RxDoctor Payments Data

Tejal Shah, MD

Internal Medicine · Houston, TXNPI 1063657807

Payments from drug & device makers

$1,536in general payments, 2019–2025

Across 79 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$406
  • AbbVie$193
  • AstraZeneca$178
  • Novo Nordisk$143
  • Abbott$113
  • Lilly USA, LLC$84
  • plus $419 from 13 others

What the payments were for

  • Food & beverage$1,536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,536 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$97,389
Medicare patients
290
Services billed
1,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$104,197
OzempicSemaglutide71$66,304
JardianceEmpagliflozin28$42,415
MounjaroTirzepatide32$36,130
TrulicityDulaglutide38$34,773
JanuviaSitagliptin Phosphate26$28,997
XareltoRivaroxaban22$21,144
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,374
MyrbetriqMirabegron19$12,027
LokelmaSodium Zirconium Cyclosilicate13$11,328
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,346
SynthroidLevothyroxine Sodium102$8,775
Breo ElliptaFluticasone/Vilanterol18$7,000
Repatha SureclickEvolocumab12$6,770
VascepaIcosapent Ethyl15$4,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$18$107,734111 claims
Lilly USA, LLCMounjaro, Trulicity$84$70,90370 claims
Novo NordiskOzempic$143$66,30471 claims
AstraZenecaLokelma, Breztri Aerosphere$178$20,67528 claims
GSKTrelegy Ellipta, Breo Ellipta$50$20,37436 claims
AbbVieSynthroid$193$8,775102 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$2,235167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →